Ex Parte Lind et al - Page 3


                 Appeal No.  2005-0792                                                         Page 3                  
                 Application No.  09/750,373                                                                           
                 of many cell types.”  According to appellants’ specification (page 2), each G                         
                 protein-coupled “receptor has its own characteristic primary structure, expression                    
                 pattern, ligand-binding profile, and intracellular effector system.”  In this regard,                 
                 appellants disclose (specification, bridging sentence, pages 2-3), “a need exists                     
                 for G protein-coupled receptors that have been identified and show promise as                         
                 targets for therapeutic intervention in a variety of animals, including humans.”                      
                        According to the specification (page 13), “[t]he present invention provides                    
                 purified and isolated polynucleotides … that encode unknown G protein-coupled                         
                 receptors heretofore termed novel GPCRs, or nGPCRs.”  Appellants disclose                             
                 (Specification, page 14), the nucleic acid of SEQ ID NO:12 was detected in brain                      
                 tissue indicating that the “nGPCR-[10071] protein” encoded by this sequence is a                      
                 neuroreceptor.  The specification, however, also indicates that “significant                          
                 expression” of the nucleic acid of SEQ ID NO:12 was also “observed in lymph                           
                 node, thyroid gland, and testis.”  Specification, page 99.  Based on this                             
                 observation, appellants postulate (Specification, bridging paragraph, pages 99-                       
                 100) that                                                                                             
                        [e]xpression of nGPCR-1007 in these tissues provides an indication                             
                        that modulators[2] of nGPCR[-1007] activity have utility for treating                          
                        metabolic diseases (e.g., type 2 diabetes, obesity, anorexia,                                  
                        hypertension, atherosclerosis, etc.); and thyroid disorders (e.g.[,]                           
                        thyroitoxicosis, myxoedema); inflammatory conditions (e.g., Chron’s                            
                        disease); rheumatoid arthritis; autoimmune disorders; movement                                 
                        disorders; CNS disorders (e.g., pain including migraine; stroke;                               
                        psychotic and neurological disorders; including anxiety, mental                                
                        disorder, manic depression, anxiety, generalized anxiety disorder,                             
                                                                                                                       
                 1 See Table 1 (specification, page 13), wherein nGPCR-1007 is disclosed to be encoded by SEQ          
                 ID NO: 12.                                                                                            
                 2 We emphasize that claim 25 is drawn to an isolated nucleic acid molecule comprising SEQ ID          
                 NO:12, not a modulator of a protein encoded by SEQ ID NO:12.                                          





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  Next 

Last modified: November 3, 2007